Polivy Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Polivy market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to the increasing prevalence of diffuse large B-cell lymphoma, the rise in the number of clinical trials, higher healthcare expenditure in oncology research, growing diagnosis rates, and the expanding availability of targeted therapies.

Growth during the market's forecast period can be attributed to the rising incidence of cancer, increasing demand for personalized medicine, growing patient populations, improved health insurance coverage, and the expanding use of digital health tools. Key trends during this period include advancements in targeted drug delivery systems, the development of subcutaneous formulations, improvements in intravenous infusion methods, the creation of long-acting formulations, and the integration of Polivy into early-stage lymphoma treatments.

The increasing incidence of diffuse large B-cell lymphoma (DLBCL) is expected to drive the growth of the Polivy market. DLBCL is the most common type of non-Hodgkin lymphoma (NHL) and is a highly aggressive form of blood cancer that originates from B-lymphocytes, which are critical for immune system function. Several factors contribute to the rising incidence of DLBCL, including an aging population, higher rates of immunosuppression due to conditions such as HIV/AIDS and organ transplants, and environmental exposures that increase the risk of the disease. Polivy is used in combination with chemotherapy to treat relapsed or refractory DLBCL in patients who have already undergone previous treatments. For instance, a report published in July 2024 by the Royal College of Pathologists highlighted that approximately 5,500 individuals in the UK are diagnosed with DLBCL each year, with about 30% of these patients experiencing refractory disease or relapse shortly after initial treatment. This growing incidence of DLBCL is driving the demand for Polivy.

Rising healthcare spending is also expected to accelerate the adoption of Polivy in the coming years. Healthcare spending refers to the total financial resources allocated for medical services, pharmaceuticals, hospital care, and preventive care, funded through government budgets, private insurance, and out-of-pocket payments. Factors such as a growing global population, greater demand for healthcare services, advancements in medical technology, the prevalence of chronic diseases, and rising healthcare costs contribute to the increase in spending. Higher healthcare spending benefits Polivy by supporting its use in treating moderate-to-high-risk DLBCL and high-grade B-cell lymphoma (HGBL). Increased investment in healthcare also enhances market access and adoption of innovative cancer therapies. For example, in May 2024, the Office for National Statistics reported that healthcare spending in the UK reached approximately $292 billion in 2023, reflecting a 5.6% increase from the previous year. This rise in healthcare spending is helping drive the growth of the Polivy market.

The increase in oncology procedures is another factor expected to fuel the growth of the Polivy market. Oncology procedures encompass medical interventions, tests, and treatments used to diagnose and manage cancer, including surgery, chemotherapy, and radiation therapy. The rise in oncology procedures is primarily driven by the growing incidence of cancer, improved survival rates that result in a growing population of cancer survivors, and the complexity of modern cancer treatments that require more frequent medical interventions. Polivy is used in oncology to treat relapsed or refractory DLBCL by targeting CD79b on cancerous B-cells and delivering chemotherapy directly to them. In January 2023, NHS England reported that over 320,000 individuals received cancer treatment between November 2021 and October 2022, marking the highest number recorded and an increase of more than 8,000 compared to the same period before the pandemic. This surge in oncology procedures is contributing to the growth of the Polivy market.

The key company operating in the polivy market is F. Hoffmann-La Roche Ltd. (Genentech Inc.)

North America was the largest region in the polivy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in polivy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the polivy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Polivy (polatuzumab vedotin) is an antibody-drug conjugate used to treat diffuse large B-cell lymphoma, a type of non-Hodgkin lymphoma. It is specifically indicated for adult patients with relapsed or refractory diffuse large B-cell lymphoma after at least two prior therapies. Polivy can also be used as a first-line treatment in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone for patients with moderate- to high-risk diffuse large B-cell lymphoma.

The primary indications for Polivy are previously untreated diffuse large B-cell lymphoma and relapsed or refractory diffuse large B-cell lymphoma. Previously untreated diffuse large B-cell lymphoma is an aggressive form of cancer that affects white blood cells and has not received prior treatment, requiring prompt medical intervention. Polivy is administered as part of combination therapy to treat this condition effectively. It is delivered in the form of injectable solutions and distributed through various channels, including direct sales, pharmaceutical wholesalers, and online pharmacies.

The polivy market research report is one of a series of new reports that provides polivy market statistics, including the polivy industry's global market size, regional shares, competitors with a polivy market share, detailed polivy market segments, market trends and opportunities, and any further data you may need to thrive in the polivy industry. This polivy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The polivy market consists of sales of polivy (polatuzumab vedotin) injections in 30 mg and 140 mg vials. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.